Aug 2026· Frontiers in Cell and Developmental Biology· Vol 14· 0 citations· 96 references
Medicine
TL;DR
This study synthesizes the latest advances in mitochondrial-targeted therapies, framing them within a “Mitochondrial Ecological Restoration” perspective, and analyzes the molecular mechanisms by which mitochondrial-targeted therapies modulate oxidative stress, mitochondrial dynamics, mitophagy and neuroinflammation.
Abstract
Alzheimer’s disease (AD), the most prevalent cause of dementia, lacks definitive cures despite decades of research focused on amyloid-beta (Aβ) and tau pathologies. Emerging evidence positions mitochondrial dysfunction not merely as a downstream consequence, but as the epicenter linking aging, metabolic failure, and neuroinflammation in AD pathogenesis. This study synthesizes the latest advances in mitochondrial-targeted therapies, framing them within a “Mitochondrial Ecological Restoration” perspective. I analyze the molecular mechanisms by which mitochondrial-targeted therapies modulate oxidative stress, mitochondrial dynamics, mitophagy and neuroinflammation, and evaluate their translational potential. Accumulating evidence indicates that strategies ranging from antioxidants (e.g., MitoQ) to mitophagy enhancement (e.g., Spautin-1) and biogenesis activation (e.g., PGC-1α Activator) have demonstrated efficacy in preclinical models. These interventions theoretically interrupt the pathological cycle between proteotoxicity and bioenergetic crisis. While challenges in blood-brain barrier (BBB) penetration and target specificity persist, the field is shifting from single-target scavenging to combinatorial ecosystem repair. Future success will require precise delivery systems, early biomarkers, and a paradigm shift toward treating the neuron as a metabolic ecosystem, though substantial translational challenges remain.
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder worldwide. Conventional downstream interventions targeting β-amyloid (Aβ) and tau proteins have repeatedly failed in clinical practice, and mitochondrial functional decline has been identified as the core upstream driver of AD pathogenesis. Focus...
Xiong Li, Rui Wan, Yu-Meng Wu et al.· Ageing Research Reviews· 0 citations
A organelle-centered perspective will clarify AD pathogenesis and help guide the development of next-generation neuroprotective therapies, and highlight the essential requirements for building one, centered on synaptic mitochondrial bioenergetics and quality control.
Yu-Xin Wang, Wei-Dong Wu, Li-Shuang Yan et al.· Frontiers in Pharmacology· 0 citations
The alterations in glucose metabolism and mitochondrial metabolism in neurons, astrocytes and microglia in AD and their relationship with neuroinflammation are summarized, while also discussing some unaddressed questions, outlining therapeutic strategies, and future promising directions.
Yinuo Lei, Liyang Liu, Yi Tang· Ageing Research Reviews· 0 citations
Overall, this review makes a case for integrative, pathway-based therapeutic models, and multiple approaches may facilitate for drug development, biomarker identification and patient management in Alzheimer's disease.
This integrated framework reframes PD as a disorder of impaired cellular maintenance rather than solely a consequence of late-stage degenerative processes, and provides a translational shift from mechanism-based biomarkers to early detection of mitochondrial failure and supports therapeutic strategies aimed at restorin...
Oscar Arias-Carrión, Magdalena Guerra-Crespo, L. O. Soto-Rojas et al.· Frontiers in Pharmacology· 0 citations
Alzheimer's disease (AD) is the leading cause of dementia and remains a major global health challenge. Although current disease-modifying therapies primarily target amyloid-β and tau pathology, their clinical efficacy is limited. Increasing evidence indicates that AD is a multifactorial disorder involving neuroinflamma...
Nataliya V. Izhytska, Katazyna Anna Sobczyk, Karolina Ogrodnik et al.· Wiadomosci lekarskie· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.